Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access programme

Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access programme

Show other versions (1)

Despite Uganda’s success in lowering the rate of HIV infection, numbers of people already infected and progressing to AIDS continue to rise. The JCRC pioneered the use of antiretroviral drugs in Africa since 1992, and developed a successful model that incorporates drugs logistics, adherence and sus...

Full description

Bibliographic Details
Main Authors:	Peter Mugyenyi, Cissy Kityo, Samson Kibende, Francis Ssali, Goeffrey Kabuye, Thomas Otim, Stefano Tugume, Rose Byaruhanga, Michael Kabugo
Format:	Article
Language:	English
Published:	University of the Free State 2006-01-01
Series:	Acta Academica
Online Access:	http://196.255.246.28/index.php/aa/article/view/1110

Similar Items

Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access programme
by: Peter Mugyenyi, et al.
Published: (2006-01-01)

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.
by: Steven J Reynolds, et al.
Published: (2010-04-01)

The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda
by: Odere Mathew, et al.
Published: (2009-07-01)

Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.
by: Francis Bajunirwe, et al.
Published: (2019-01-01)

Financial Resource Capacity Development Strategies and Public Secondary School Growth in Kira Municipality, Wakiso District, Uganda
by: Kabuye Rehmah, et al.
Published: (2022-12-01)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
by: Antonieta Medina Lara, et al.
Published: (2012-01-01)

Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.
by: Seth C Inzaule, et al.
Published: (2016-01-01)

Correction: Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.
by: Seth C Inzaule, et al.
Published: (2017-01-01)

Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.
by: Steven Baveewo, et al.
Published: (2011-01-01)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
by: Mugyenyi, P, et al.
Published: (2010)

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.
by: Jaganath, D, et al.
Published: (2014)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
by: Cissy Kityo, et al.
Published: (2014-01-01)

Patients’ recommendations for a patient-centred public antiretroviral therapy programme in eThekwini, KwaZulu-Natal
by: Delarise M. Mulqueeny, et al.
Published: (2017-03-01)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
by: Lara, A, et al.
Published: (2012)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
by: Munderi, P, et al.
Published: (2011)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
by: Stöhr, W, et al.
Published: (2011)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
by: Paton, N, et al.
Published: (2014)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
by: Reid, A, et al.
Published: (2008)

Pałając pragnieniem. Narodziny fotografii
by: Goeffrey Batchen
Published: (2018-05-01)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
by: Hellen Musana, et al.
Published: (2021-04-01)

Renal impairment in a rural African antiretroviral programme
by: Lessells Richard J, et al.
Published: (2009-08-01)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
by: Hakim, J, et al.
Published: (2017)

Voluntary HIV counselling and testing among men in rural western Uganda: Implications for HIV prevention
by: Byaruhanga Simon, et al.
Published: (2008-07-01)

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.
by: Jessica E Haberer, et al.
Published: (2011-04-01)

Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
by: Seth Inzaule, et al.
Published: (2014-01-01)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
by: Kityo, C, et al.
Published: (2014)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

World Health Organization dimensions of adherence to antiretroviral therapy: A study at antiretroviral therapy centre, Aligarh
by: Yasir Alvi, et al.
Published: (2019-01-01)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

Social capital and resilience among people living on antiretroviral therapy in resource-poor Uganda.
by: Esther Kalule Nanfuka, et al.
Published: (2018-01-01)

Evaluation of the Nigerian national antiretroviral (ARV) treatment training programme
by: E Oni Idigbe, et al.
Published: (2006-11-01)

The role of a multidisciplinary team meeting in an antiretroviral treatment programme
by: C van deventer, et al.
Published: (2009-07-01)

The Keiskamma AIDS Treatment programme: Evaluation of a community-based antiretroviral programme in a rural setting
by: Graham P. Hofmeyr, et al.
Published: (2009-03-01)

Long-term antiretroviral treatment adherence in HIV-infected adolescents and adults in Uganda: a qualitative study
by: Inzaule, S, et al.
Published: (2016)

Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage
by: Boerma J Ties, et al.
Published: (2006-01-01)

Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.
by: Inzaule, S, et al.
Published: (2016)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
by: Paton, N, et al.
Published: (2014)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
by: Lisa L Ross, et al.
Published: (2019-01-01)